Prostate cancer that spreads to the bone triggers the destruction of bone tissue that, in turn, thwarts the effectiveness of immune checkpoint inhibitors by blocking the development of T cells that are crucial to successful treatment, researchers from The University of Texas MD Anderson Cancer Center, USA, report in Cell.
The discoveries by a team led by Padmanee Sharma, M.D., Ph.D., professor of Genitourinary Medical Oncology and Immunology at MD Anderson, explain why immunotherapy has been largely unsuccessful against prostate cancer bone metastases and point to a possible combination that could reverse the resistance.
Their findings also highlight the need to look at metastatic cancer in a different light.
“We tend to think of stage 4 disease as being uniform, but it’s not all the same,” Sharma said. “We need to be more thoughtful about the immune microenvironment in different areas of metastasis to take into account different immune responses in those microenvironments when we develop treatments.”
Research points to anti-TGF-β, anti-CTLA-4 combination
The team found that the bone destruction caused by tumours leads to massive production of transformational growth factor-beta (TGF-β), a protein that causes helper T cells to polarise into Th17 CD4 cells instead of the Th1 CD4 effector cells required to trigger an anti-tumour immune response.
Combining anti-TGF-β treatment with an inhibitor of the CTLA-4 checkpoint on T cells stifled growth of bone metastases in a mouse model.
“We’re working to develop a combination clinical trial of anti-CTLA-4 and anti- TGF-β for metastatic prostate cancer,” Sharma stated.
A majority of men with prostate cancer have their cancer progress to metastatic castration-resistant disease, which is almost uniformly lethal.
About 70-80 percent of men with stage 4 prostate cancer develop bone metastases.
While recent research by Sharma and colleagues showed that a combination of anti-CTLA-4 (ipilimumab) and anti-PD-1 (nivolumab) checkpoint inhibitors helps some men with stage 4 prostate cancer, it largely failed against bone metastasis.
To understand this issue, Sharma’s team first examined pre- and post-treatment bone marrow from patients for clues about treatment resistance.
They further explored their observations in mouse models of metastatic prostate cancer and tested combination therapies – “reverse translation” of their findings from people.
Absence of Th1 CD4 T cells
When it works, immune checkpoint blockade expands Th1 CD4 effector cells, which leads to activation of killer CD8 T cells and generation of long-term memory cells.
The team found plenty of Th1 effectors in the soft tissues of patients treated with ipilimumab, but these crucial cells were largely absent in the bones, where they instead found abundant Th17 cells.
“The important point here is the absence of the Th1 cells,” Sharma noted.
Cytokines polarise helper cells to different types, and in the bone microenvironment they produce an abundance of Th17 cells.
The function of the Th17 cells there is not known.
The team developed two mouse models of metastatic disease – one that represented bone metastases and a subcutaneous model that represented primary prostate cancer or soft-tissue metastases.
As in humans, treatment with ipilimumab and nivolumab combination shrank tumours and extended survival of the mice with soft-tissue metastases but had minimal effects on the tumours and survival of those with bone metastases.
Treatment expanded tumour infiltrating CD4 and CD8 T cells in both soft tissue and bones, but failed to inhibit growth of bone tumours.
Mass cytometry analysis of the T cells showed why.
The CD4 T cells in the bone tumours were only of the Th17 and regulatory T cell (Treg) lineages.
Tregs inhibit immune response.
There were no Th1 effector cells.
In the subcutaneous model, Th1 effectors were detected before treatment and then greatly increased after treatment while Th17 and Tregs decreased.
TGF-β protects bone tumours
Lack of Th1 cells in the bone marrow suggested a distinct cytokine profile in the bone microenvironment.
The team analysed levels of 13 cytokines in the tumour-bearing and tumour-free femurs of the mice.
They found significant elevation of TGF-β, known to restrain Th1 lineage and drive both Th17 and Treg development.
Th17 also requires the presence of Interleukin-6, which was found abundantly, as expected, in the bone marrow.
Bone metastasis triggers abnormal bone remodelling, and bone components are known as a major reservoir of TGF-β.
The team hypothesised that bone matrix remodelling causes the high TGF-β levels in prostate bone metastases.
Their experiments confirmed that osteoclasts – cells that degrade bone – activated by tumours release excessive amounts of TGF-β while they erode bone surfaces.
To test the hypothesis in humans, they compared TGF-β levels in the bone marrow of healthy donors and prostate cancer patients with and without bone metastases.
There was no difference in TGF-β levels between healthy controls and patients without bone metastases, while patients with bone tumours had aberrantly high levels of TGF-β in their bones.
Blocking TGF-β restores Th1 cells and boosts immunotherapy
Treating mice with bone metastases with the ipilimumab and nivolumab combination failed to stop tumour growth.
But adding anti- TGF-β to the immunotherapy combination halted tumour growth.
Anti- TGF-β and ipilimumab alone also stifled bone metastasis growth.
This combination also increased the frequency of Th1 cells and decreased Tregs in the bone microenvironment.